Starpharma IPO év
Mi az Starpharma IPO év?
A IPO év az Starpharma Holdings Limited - 2000
Mi a IPO év meghatározása?
A kezdeti nyilvános ajánlattétel olyan nyilvános ajánlattétel, amelyben a társaság részvényeit általában olyan intézményi befektetőknek adják el, akik viszont értékpapírcserében először értékesítik a nagyközönségnek.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO év a Health Care szektor a ASX-on cégekben a Starpharma -hoz képest
Mit csinál Starpharma?
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
ipo év -hoz hasonló cégek Starpharma
- Arq nak IPO év 1999 van
- TasFoods nak IPO év 1999 van
- hopTo nak IPO év 1999 van
- aap Implantate AG nak IPO év 1999 van
- Invigor nak IPO év 1999 van
- Encavis AG nak IPO év 1999 van
- Starpharma nak IPO év 2000 van
- SSR Mining Inc nak IPO év 2001 van
- Bread Inc nak IPO év 2001 van
- Exact Sciences nak IPO év 2001 van
- Cross Country Healthcares nak IPO év 2001 van
- Friedman Industries nak IPO év 2001 van
- Chevron nak IPO év 2001 van